All In Biotech

Drug Trial Radar · NCT04475432

Safety and Efficacy of TP-03 for the Treatment of Demodex Blepharitis

Randomized, Controlled, Multicenter, Double-Masked, Parallel, Phase 2b/3 Trial to Evaluate the Safety and Efficacy of TP-03 for the Treatment of Demodex Blepharitis

Last checked: Nov 20, 2026Latest source record: Dec 21, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 421 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

421

Actual

Start

Sep 9, 2020

Primary completion

May 4, 2021

Study completion May 4, 2021

Sponsor

Lead sponsor
Tarsus Pharmaceuticals, Inc.Industry
Sponsor type
Industry
First posted
Jul 17, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to compare the safety and efficacy of TP-03, 0.25%, an eyedrop, to its vehicle control for the treatment of blepharitis due to Demodex, a microscopic mite frequently found in human hair follicles. The hypothesis for the study is the proportion of participants cured at Day 43 with treatment by TP-03, 0.25%, is greater than the proportion cured by treatment with its vehicle.

Conditions

  • Blepharitis

Interventions

  • TP-03, 0.25%Drug

    TP-03, lotilaner ophthalmic solution, 0.25%, administered twice a day

  • TP-03 VehicleDrug

    Vehicle of TP-03 ophthalmic solution, administered twice a day

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of Participants Cured Based on a Collarette Score at Day 43.Time frame: 43 days

Locations

15 sites in 1 country. Site status is shown where the registry gives one.

  • Cornea and Cataract Consultants of Arizona

    Phoenix, Arizona

  • Eye Research Foundation

    Newport Beach, California

  • Visionary Eye Institute

    Newport Beach, California

  • Vision Institute

    Colorado Springs, Colorado

  • Midwest Cornea Associates, LLC

    Carmel, Indiana

  • Washburn Research LLC

    Indianapolis, Indiana

  • The Eye Care Institute

    Louisville, Kentucky

  • Andover Eye Associates

    Andover, Massachusetts

  • Ophthalmology Associates

    St Louis, Missouri

  • Oculus Research, Inc at EyecareCenter

    Raleigh, North Carolina

  • Vita Eye Clinic

    Shelby, North Carolina

  • Scott & Christie and Associates, PC

    Cranberry Township, Pennsylvania

  • Total Eye Care, P.A.

    Memphis, Tennessee

  • Alpine Research Organization

    Layton, Utah

  • Piedmont Eye Center

    Lynchburg, Virginia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.